Ginkgo Bioworks Holdings Inc (NYSE: DNA) on Friday, plunged -11.97% from the previous trading day, before settling in for the closing price of $11.11. Within the past 52 weeks, DNA’s price has moved between $5.26 and $64.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 104.75% over the past five years. The company achieved an average annual earnings per share of 45.22%. With a float of $36.49 million, this company’s outstanding shares have now reached $41.37 million.
Let’s look at the performance matrix of the company that is accounted for 1218 employees. In terms of profitability, gross margin is 63.73%, operating margin of -271.32%, and the pretax margin is -298.94%.
Ginkgo Bioworks Holdings Inc (DNA) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ginkgo Bioworks Holdings Inc is 33.02%, while institutional ownership is 47.97%. The most recent insider transaction that took place on Jan 10 ’25, was worth 1,067. Before that another transaction happened on Jan 06 ’25, when Company’s insider sold 324 for $11.72, making the entire transaction worth $3,797. This insider now owns 7,288 shares in total.
Ginkgo Bioworks Holdings Inc (DNA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 45.22% per share during the next fiscal year.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Ginkgo Bioworks Holdings Inc (DNA) is currently performing well based on its current performance indicators. A quick ratio of 5.79 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -12.90, a number that is poised to hit -1.50 in the next quarter and is forecasted to reach -5.81 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
Ginkgo Bioworks Holdings Inc (NYSE: DNA) saw its 5-day average volume 1.38 million, a negative change from its year-to-date volume of 1.45 million. As of the previous 9 days, the stock’s Stochastic %D was 48.69%. Additionally, its Average True Range was 1.12.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 60.35%, which indicates a significant increase from 31.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 112.79% in the past 14 days, which was higher than the 107.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.02, while its 200-day Moving Average is $16.34. Nevertheless, the first resistance level for the watch stands at $10.47 in the near term. At $11.16, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.52. If the price goes on to break the first support level at $9.43, it is likely to go to the next support level at $9.07. The third support level lies at $8.38 if the price breaches the second support level.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
Market capitalization of the company is 562.14 million based on 57,479K outstanding shares. Right now, sales total 251,460 K and income totals -892,870 K. The company made 89,050 K in profit during its latest quarter, and -56,400 K in sales during its previous quarter.
